Skip to main content
logo
Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,345.00
-90.00 (-3.70%)
At close: Jul 24, 2026

Vivozon Pharmaceutical Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
54,86459,34387,60171,31851,56457,560
Revenue Growth
-36.45%-32.26%22.83%38.31%-10.42%32.04%
Gross Profit
20,40024,18445,40731,32121,43719,639
Operating Income
-19,682-19,166-1,8004,709-9,806-19,615
Net Income
-34,210-32,424-9,982-3,357-39,906-69,457
Earnings Per Share
-682.32-654.88-209.00-70.35-917.27-2130.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
16,1755,1589,98817,72126,40064,055
Total Debt
36,16042,34136,50041,61560,31084,115
Net Cash (Debt)
-19,985-37,183-26,512-23,894-33,910-20,060
Net Cash Growth
------
Net Cash Per Share
-398.60-751.00-555.09-500.74-779.45-615.13

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-10,973-6,8695,7312,992-3,323-17,496
Capital Expenditures
-519.54-1,412-8,450-4,523-6,491-10,111
Free Cash Flow
-11,493-8,281-2,719-1,532-9,814-27,608
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
37.18%40.75%51.83%43.92%41.57%34.12%
Operating Margin
-35.88%-32.30%-2.05%6.60%-19.02%-34.08%
Pretax Margin
-62.11%-54.39%-12.03%-3.03%-49.15%-131.77%
Profit Margin
-62.36%-54.64%-11.39%-4.71%-77.39%-120.67%
FCF Margin
-20.95%-13.95%-3.10%-2.15%-19.03%-47.96%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
2.573.383.882.032.893.23